[go: up one dir, main page]

WO2009033815A3 - Utilisation d'un peptide en tant qu'agent thérapeutique - Google Patents

Utilisation d'un peptide en tant qu'agent thérapeutique Download PDF

Info

Publication number
WO2009033815A3
WO2009033815A3 PCT/EP2008/008163 EP2008008163W WO2009033815A3 WO 2009033815 A3 WO2009033815 A3 WO 2009033815A3 EP 2008008163 W EP2008008163 W EP 2008008163W WO 2009033815 A3 WO2009033815 A3 WO 2009033815A3
Authority
WO
WIPO (PCT)
Prior art keywords
pro
ala
gly
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/008163
Other languages
English (en)
Other versions
WO2009033815A2 (fr
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mondobiotech Laboratories AG
Original Assignee
Mondobiotech Laboratories AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Laboratories AG filed Critical Mondobiotech Laboratories AG
Publication of WO2009033815A2 publication Critical patent/WO2009033815A2/fr
Publication of WO2009033815A3 publication Critical patent/WO2009033815A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de la combinaison des composés peptidiques Ala-Pro-Gly-Pro-Arg-OH et Lys-Trp-Lys-Leu-Phe-Lys-Lys-lle-Glu-Lys- Val-Gly-Gln-Asn-lle-Arg-Asp-Gly-lle-lle-Lys-Ala-Gly-Pro-Ala-Val-Ala-Val-Val-Gly-Gln- Ala-Thr-Gln-lle-Ala-Lys-NH2 en tant que composés polythérapeutiques destinés à la prophylaxie et/ou au traitement du cancer, d'une maladie cardiaque et vasculaire, d'une maladie infectieuse, d'une maladie fibreuse, d'une maladie inflammatoire, d'une maladie neurodégénérative ou d'une maladie auto-immune.
PCT/EP2008/008163 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique Ceased WO2009033815A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017761.3 2007-09-11
EP07017754 2007-09-11
EP07017754.8 2007-09-11
EP07017761 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009033815A2 WO2009033815A2 (fr) 2009-03-19
WO2009033815A3 true WO2009033815A3 (fr) 2009-06-04

Family

ID=40404889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008163 Ceased WO2009033815A2 (fr) 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique

Country Status (1)

Country Link
WO (1) WO2009033815A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111329992B (zh) * 2020-03-03 2023-04-07 青岛农业大学 一种无抗高活性乳化抗菌肽的结肠炎修复剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608783B2 (en) * 1986-11-20 1991-04-18 Harkness Pharmaceuticals, Inc. Agent for the regulation of the appetite or a sleeping agent
US5635479A (en) * 1992-08-31 1997-06-03 Magainin Pharmaceuticals Inc. Treatment of gynecological malignancies with biologically active peptides
WO2007064634A2 (fr) * 2005-11-30 2007-06-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Enterostatine utile comme inhibiteur de l'angiogenese
WO2007070564A2 (fr) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Methodes permettant de traiter l'obesite au moyen d'enterostatine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608783B2 (en) * 1986-11-20 1991-04-18 Harkness Pharmaceuticals, Inc. Agent for the regulation of the appetite or a sleeping agent
US5635479A (en) * 1992-08-31 1997-06-03 Magainin Pharmaceuticals Inc. Treatment of gynecological malignancies with biologically active peptides
WO2007064634A2 (fr) * 2005-11-30 2007-06-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Enterostatine utile comme inhibiteur de l'angiogenese
WO2007070564A2 (fr) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Methodes permettant de traiter l'obesite au moyen d'enterostatine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALBIOL MATANIC VANESA C ET AL: "Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS APR 2004,, vol. 23, no. 4, 1 April 2004 (2004-04-01), pages 382 - 389, XP002515450 *
WACHINGER M ET AL: "Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 79, no. 4, 1 April 1998 (1998-04-01), pages 731 - 740, XP002421830, ISSN: 0022-1317 *

Also Published As

Publication number Publication date
WO2009033815A2 (fr) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009033821A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043518A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043522A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
LTC2435432I2 (lt) Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
WO2007135026A3 (fr) Ptéridines substituées
WO2011039735A3 (fr) Composés ayant une activité inhibitrice et utilisations de ceux-ci
WO2010007166A3 (fr) Traitement de maladies intestinales inflammatoires par des bêta-défensines de mammifères
WO2011014825A3 (fr) Petites molécules anti-angiogéniques et procédés d'utilisation
WO2009033819A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2012061390A3 (fr) Compositions et procédés thérapeutiques
ZA200904975B (en) Use of chitosans for the treatment of nail inflammatory diseases
WO2010094734A3 (fr) Procédés d'identification de composés utiles pour le diagnostic et le traitement de maladies liées à une inflammation
WO2009033813A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043525A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033818A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033814A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046875A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046872A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033816A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033809A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033820A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033815A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2008009426A9 (fr) Dérivés de 5-cyano-prostacycline utilisés comme agents dans le traitement de maladies auto-immunes
WO2009043519A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08830024

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08830024

Country of ref document: EP

Kind code of ref document: A2